Aesthetic plastic surgery · 2026
Intradermal Injections of 10% Glucose (Sihler G) for Scalp Hair Regrowth: A Randomized, Evaluator-Blinded Pilot Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yi Kyu-Ho, Sydorchuk Olena, Lee Suyeon, Sobchyshyn Mariya, Kim Tae-Hyun, Lee Sa Rang, Park Sijun, Chang-Il Yoon, Kyu-Eun Lee
Аннотация
BACKGROUND: Androgenetic alopecia (AGA) is a common non-scarring alopecia with substantial psychosocial burden. Minoxidil and 5α-reductase inhibitors remain standards of care but require prolonged adherence and do not fully address the dermal microenvironment.
OBJECTIVE: To evaluate efficacy and safety of intradermal 10% glucose combined with non-cross-linked hyaluronic acid (NHA) versus NHA alone for scalp hair regrowth.
METHODS: In this prospective, single-center, randomized, evaluator-blinded pilot study, 40 adults with mild-to-moderate AGA (Norwood-Hamilton II-IV or Ludwig I-II) were randomized 1:1 to receive intradermal 10% glucose + NHA (Sihler G, Sihler Inc., Korea) or NHA alone. Participants underwent five sessions at 3-week intervals (weeks 0-12). This pilot study was not prospectively registered. The primary end point was change in terminal hair density (hairs/cm2) in a fixed target area from baseline to week 18. Secondary outcomes included hair shaft diameter, global photographic assessments, responder rates, and patient-reported outcomes.
RESULTS: Thirty-eight participants completed the study (19 per group). At week 18, mean terminal hair density increased by + 19.3 ± 8.1 hairs/cm2 with glucose+NHA and by + 6.2 ± 7.5 hairs/cm2 with NHA alone (between-group difference 13.1 hairs/cm2; 95% CI 7.6-18.7; p < 0.001). Mean hair shaft diameter increased by + 12.8% ± 6.9 versus + 4.1%±6.1 (p = 0.002). Responder rates (≥ 15% density increase) were 74% versus 26% (p = 0.003). Adverse events were mild and transient; no serious events occurred.
CONCLUSION: In this pilot RCT, intradermal 10% glucose combined with NHA produced greater improvements in objective and subjective hair outcomes than NHA alone, with a favorable shortterm safety profile. Larger, longer trials are warranted.
LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
OBJECTIVE: To evaluate efficacy and safety of intradermal 10% glucose combined with non-cross-linked hyaluronic acid (NHA) versus NHA alone for scalp hair regrowth.
METHODS: In this prospective, single-center, randomized, evaluator-blinded pilot study, 40 adults with mild-to-moderate AGA (Norwood-Hamilton II-IV or Ludwig I-II) were randomized 1:1 to receive intradermal 10% glucose + NHA (Sihler G, Sihler Inc., Korea) or NHA alone. Participants underwent five sessions at 3-week intervals (weeks 0-12). This pilot study was not prospectively registered. The primary end point was change in terminal hair density (hairs/cm2) in a fixed target area from baseline to week 18. Secondary outcomes included hair shaft diameter, global photographic assessments, responder rates, and patient-reported outcomes.
RESULTS: Thirty-eight participants completed the study (19 per group). At week 18, mean terminal hair density increased by + 19.3 ± 8.1 hairs/cm2 with glucose+NHA and by + 6.2 ± 7.5 hairs/cm2 with NHA alone (between-group difference 13.1 hairs/cm2; 95% CI 7.6-18.7; p < 0.001). Mean hair shaft diameter increased by + 12.8% ± 6.9 versus + 4.1%±6.1 (p = 0.002). Responder rates (≥ 15% density increase) were 74% versus 26% (p = 0.003). Adverse events were mild and transient; no serious events occurred.
CONCLUSION: In this pilot RCT, intradermal 10% glucose combined with NHA produced greater improvements in objective and subjective hair outcomes than NHA alone, with a favorable shortterm safety profile. Larger, longer trials are warranted.
LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .